« Previous AbstractComparison of the benzene sorption properties of metal organic frameworks: influence of the textural properties    Next AbstractNew screening method for lung cancer by detecting volatile organic compounds in breath »

Transl Res

Title:		"MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease"
Author(s):		Belcher JD; Nguyen J; Chen C; Abdulla F; Conglin R; Ivy ZK; Cummings J; Dudler T; Vercellotti GM;
Address:		"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota. Electronic address: belcher@umn.edu. Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota. Omeros Corporation, Seattle, Washington"
Journal Title:		Transl Res
Year:		2022
Volume:		20220722
Issue:
Page Number:		1 - 12
DOI:		10.1016/j.trsl.2022.06.018
ISSN/ISBN:		1878-1810 (Electronic) 1931-5244 (Print) 1878-1810 (Linking)
Abstract:		"Patients with sickle cell disease (SCD) have ongoing hemolysis that promotes endothelial injury, complement activation, inflammation, vaso-occlusion, ischemia-reperfusion pathophysiology, and pain. Complement activation markers are increased in SCD in steady-state and further increased during vaso-occlusive crisis (VOC). However, the mechanisms driving complement activation in SCD have not been completely elucidated. Ischemia-reperfusion and heme released from hemoglobin during hemolysis, events that characterize SCD pathophysiology, can activate the lectin pathway (LP) and alternative pathway (AP), respectively. Here we evaluated the role of LP and AP in Townes sickle (SS) mice using inhibitory monoclonal antibodies (mAb) to mannose binding lectin (MBL)-associated serine protease (MASP)-2 or MASP-3, respectively. Townes SS mice were pretreated with MASP-2 mAb, MASP-3 mAb, isotype control mAb, or PBS before they were challenged with hypoxia-reoxygenation or hemoglobin. Pretreatment of SS mice with MASP-2 or MASP-3 mAb, markedly reduced Bb fragments, C4d and C5a in plasma and complement deposition in the liver, kidneys, and lungs collected 4 hours after challenge compared to control mAb-treated mice. Consistent with complement inhibition, hepatic inflammation markers NF-kB phospho-p65, VCAM-1, ICAM-1, and E-selectin were significantly reduced in SS mice pretreated with MASP-2 or MASP-3 mAb. Importantly, MASP-2 or MASP-3 mAb pretreatment significantly inhibited microvascular stasis (vaso-occlusion) induced by hypoxia-reoxygenation or hemoglobin. These studies suggest that the LP and the AP are both playing a role in promoting inflammation and vaso-occlusion in SCD. Inhibiting complement activation via the LP or the AP might inhibit inflammation and prevent VOC in SCD patients"
Keywords:		"*Anemia, Sickle Cell/complications Animals Antibodies, Monoclonal/pharmacology Complement Activation Disease Models, Animal E-Selectin Heme Hemoglobins Hemolysis Hypoxia Inflammation Intercellular Adhesion Molecule-1 Mannose-Binding Lectins Mannose-Bindin;"
Notes:		"MedlineBelcher, John D Nguyen, Julia Chen, Chunsheng Abdulla, Fuad Conglin, Ruan Ivy, Zalaya K Cummings, Jason Dudler, Thomas Vercellotti, Gregory M eng R01 HL114567/HL/NHLBI NIH HHS/ T32 HL007062/HL/NHLBI NIH HHS/ Research Support, N.I.H., Extramural 2022/07/26 Transl Res. 2022 Nov; 249:1-12. doi: 10.1016/j.trsl.2022.06.018. Epub 2022 Jul 22"